KYMR logo

KYMR
Kymera Therapeutics Inc

839
Mkt Cap
$6.38B
Volume
671,535.00
52W High
$103.00
52W Low
$19.45
PE Ratio
-21.24
KYMR Fundamentals
Price
$78.16
Prev Close
$80.18
Open
$80.18
50D MA
$80.00
Beta
1.62
Avg. Volume
861,084.94
EPS (Annual)
-$3.69
P/B
4.02
Rev/Employee
$164,752.10
$5,808.19
Loading...
Loading...
News
all
press releases
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 91,250 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 24,727 shares of the company's stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $80.26, for a total transaction of $1,984,589.02. Following the transaction, the chief...
MarketBeat·3d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction...
MarketBeat·3d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4% - What's Next?
Kymera Therapeutics (NASDAQ:KYMR) Trading Up 8.4% - Should You Buy...
MarketBeat·3d ago
News Placeholder
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-two brokerages that are currently covering the stock...
MarketBeat·5d ago
News Placeholder
Hudson Bay Capital Management LP Grows Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Hudson Bay Capital Management LP grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 362.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,134 shares of the company's stock after buying an additional 18...
MarketBeat·6d ago
News Placeholder
Nextech Trims Kymera at a Recent High think Foolishly before acting.
Key PointsSold 62,013 shares of Kymera Therapeutics; estimated transaction value $4.19 million (based on mean unadjusted close for the quarter...
Nasdaq News: Markets·9d ago
News Placeholder
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR
HighVista Strategies LLC acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·11d ago
News Placeholder
Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR
Holocene Advisors LP bought a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities...
MarketBeat·11d ago
News Placeholder
Jefferies Financial Group Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)
Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a report on Monday. They issued a "buy" rating for the company...
MarketBeat·12d ago
<
1
2
...
>

Latest KYMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.